Core Viewpoint - Sihuan Pharmaceutical (01530) has seen a stock price increase of over 4%, currently trading at 31.66 HKD with a transaction volume of 940 million HKD, following the completion of a subscription agreement with Pfizer [1] Group 1: Subscription Agreement Details - Sihuan Pharmaceutical announced that all conditions for the subscription agreement have been met and completed on August 1, resulting in the issuance of 31.1425 million shares at a subscription price of 25.2055 HKD per share to Pfizer [1] - The net proceeds from this transaction amount to approximately 785 million HKD, with 80% allocated for enhancing the global R&D pipeline for clinical and preclinical projects, and 20% for other general corporate purposes [1] Group 2: Pfizer's Strategic Focus - CITIC Securities released a report indicating that Pfizer is focusing on four major cancer areas: breast cancer, urogenital system cancer, hematological cancer, and thoracic tumors, with plans to launch at least eight blockbuster oncology drugs by 2030 [1] - SSGJ-707, a dual-target antibody for PD-1 and VEGF, is aligned with Pfizer's core oncology treatment areas, and the company will prioritize its clinical development in lung cancer, colorectal cancer, and breast cancer to address unmet clinical needs across multiple cancer types [1]
港股异动 | 三生制药(01530)再涨超4% 公司完成向辉瑞配售股份 辉瑞研发战略与707开发高度适配